(MENAFN- GlobeNewsWire - Nasdaq) Newark, New Castle, USA, June 13, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global hypercoagulability treatment market was conducted by Growth Plus Reports in 2022 and was valued at US$ 634.11 million . The market is expected to hit a revenue CAGR of 6.8% to reach US$ 1146.32 million by 2031.

Analysis of the global market for hypercoagulability treatment indicates that the revenue share is likely to increase significantly during the forecast period. Hypercoagulability is when blood has an increased proclivity to clot, increasing the risk of major medical problems such as deep vein thrombosis, stroke, or pulmonary embolism.

Key Takeaways:

• The Anticoagulant medications, such as heparin, warfarin, dabigatran, apixaban, rivaroxaban, and edoxaban, are contributing to the market revenue growth.
• The rising prevalence of deep vein thrombosis and pulmonary embolism drives market demand.
• Deep vein thrombosis has an incidence rate of 80 instances per 100,000 persons, with a frequency of 1 case per 1000 people, according to the National Center for Biotechnology Information.

Request a Free Sample of the Research Report:

Hypercoagulability Treatment Market Scope

Report Attribute	Details
Market Size Value in 2022	US$ 634.11 million
Revenue Forecast in 2031	US$ 1146.32 million
CAGR	6.8%
Base Year for Estimation	2022
Forecast Period	2023 to 2031
Historical Year	2021
Segments Covered	Drug , Route of Administration and Region
Regional Scope	North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Recent Development in the Hypercoagulability Treatment Market:

• In July 2022, The National Blood Clot Alliance (NBCA) established the Council for Emerging Researchers in Thrombosis (CERT). CERT will serve as a forum for early career doctors and researchers working in thrombosis and thrombophilia to promote and carry out research and scientific activities on behalf of thrombosis patients.

Competitive Landscape

A list of the companies operating in the global market for hypercoagulability treatment includes:

• Novartis AG
• Teleflex Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Shenzhen Techdow Pharmaceutical Co. Ltd.

Market Drivers and Restraints:

The global hypercoagulability treatment market revenue is driven by the increased awareness of the hazards associated with hypercoagulability, as well as the significance of early diagnosis and treatment. Furthermore, direct oral anticoagulants (DOACs) and other innovative medicines, which are more convenient and have fewer side effects than older ones, also drive market revenue growth.

However, due to the high expenses, the hypercoagulability treatment market revenue growth is expected to be restrained.

Request for Customization –

Market Segmentation:

• The global hypercoagulability treatment market is segmented into heparin, warfarin, direct thrombin inhibitor, and others, based on the drug.
• The global hypercoagulability treatment market is segmented into oral and injectable, based on the route of administration.

Segmentation By Drug

Based on the drugs, the heparin segment dominates the global hypercoagulability treatment market with the largest revenue share. This large revenue share is attributed to its safety and efficacy. Heparin is often used to treat hypercoagulability diseases such as deep vein thrombosis or pulmonary embolism, which are medical emergencies that must be treated immediately. This leads to the wide usage of heparin in hospitals, contributing to the segment's revenue growth.

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global hypercoagulability treatment market. The market for hypercoagulability therapy in North America is being pushed by technical advances in developing newer, more effective anticoagulant medicines. Furthermore, the favorable payment policy for hypercoagulability therapy in North America has increased patient access to these medicines.

Report Coverage

Growth Plus Reports conducted extensive market research on the global hypercoagulability treatment market. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

INTRODUCTION

Market Ecosystem

Timeline Under Consideration

Historical Years – 2021

Base Year – 2022

Forecast Years – 2023 to 2031

Currency Used in the Report

RESEARCH METHODOLOGY

Research Approach

Data Collection Methodology

Data Sources

Secondary Sources

Primary Sources

Market Estimation Approach

Bottom Up

Top Down

Market Forecasting Model

Limitations and Assumptions

PREMIUM INSIGHTS

Current Market Trends (COVID-19 Perspective)

Key Players & Competitive Positioning (2022)

Regulatory Landscape

MARKET DYNAMICS

Drivers

Restraints/Challenges

Opportunities

GLOBAL HYPERCOAGULABILITY TREATMENT MARKET- ANALYSIS & FORECAST, BY DRUG

Heparin

Warfarin

Direct Thrombin Inhibitor

Others

GLOBAL HYPERCOAGULABILITY TREATMENT MARKET- ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION

Oral

Injectable

hypercoagulability treatment market toc

Buy this Premium Research Report:

VALUE PROPOSITIONS RELATED TO THE REPORT :

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.

CUSTOMIZATION OPTIONS :

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• 'Business Profile' of Key Players

Schedule a call with our analyst:

Visit our report store at -

Browse more latest healthcare reports:

Browse more latest healthcare reports:

anticholesteremic agents market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

glucose elevating agents market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

expat health insurance market by Service Provider (Private, Public), Indication (Emergency Medical Evacuation, Maternity Coverage, Outpatient Coverage), Term Plan (Short-Term, Long-Term) – Global Outlook & Forecast 2023-2031

veterinary euthanasia drugs market by Animal Type (Companion Animals and Farm Animals), Route of Administration (Injectable Euthanasia Drugs, Inhalational Euthanasia Drugs) – Global Outlook & Forecast 2023-2031

misme syndrome market by Treatment (Surgery, Radiotherapy, Pharmacotherapy) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020".

Tags hypercoagulability treatment Related Links

• ergocalciferol market
• leptin based therapeutics market

MENAFN13062023004107003653ID1106429867